{
    "abstract": "Background: To provide broader protection against pneumococcal disease, new vaccines containing conserved Streptococcus pneumoniae proteins are being developed. This study assessed the safety, reactogenicity and immunogenicity of four formulations containing pneumococcal proteins pneumolysin toxoid (dPly) and histidine triad protein (PhtD) in toddlers. Methods: In this phase II, multicenter, observer-blind study (www.clinicaltrials.gov: NCT00985751) conducted in the Czech Republic, toddlers (12-23 months) were randomized (1:1:1:1:1) to receive one of four investigational vaccine formulations (10 or 30. \u03bcg each of dPly and PhtD, alone or in combination with polysaccharide conjugates from the pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine [PHiD-CV]), or the licensed PHiD-CV, in a 2-dose primary series plus booster at study months 0, 2 and 6. Solicited local and general symptoms were recorded within seven days post-vaccination, unsolicited symptoms within 31 days post-vaccination, and serious adverse events (SAEs) during the entire study period. Antibody concentrations against the vaccine components were measured pre-vaccination, one month post-dose 2, pre- and one month post-booster. Results: 257 toddlers were enrolled and vaccinated. Percentages of solicited local and general symptoms following the different investigational formulations were generally within the same ranges as for PHiD-CV. After each dose, grade 3 fever (>40.0. \u00b0C, rectal measurement) was reported for maximum one toddler in each group with no differences between investigational formulations and PHiD-CV during primary vaccination. 23 SAEs were reported for 17 toddlers, with distribution balanced between all groups except the group receiving 30. \u03bcg dPly/PhtD with PHiD-CV-conjugates (no SAEs reported). None of the SAEs were considered to be vaccine-related.For all pneumococcal protein-containing formulations, anti-PhtD and anti-Ply antibody geometric mean concentrations increased from pre-vaccination to post-dose 2 and from pre- to post-booster vaccination. Conclusion: All investigational vaccine formulations were well-tolerated and immunogenic when administered to toddlers as a 2-dose primary vaccination followed by a booster dose. \u00a9 2014.",
    "author_highlights": [
        {
            "endOffset": 17917,
            "sentence": "Study of 4 investigational vaccines containing pneumococcal proteins dPly and PhtD.",
            "startOffset": 17834
        },
        {
            "endOffset": 17988,
            "sentence": "This is the first study of these investigational vaccines in toddlers.",
            "startOffset": 17918
        },
        {
            "endOffset": 18072,
            "sentence": "We assessed safety and immunogenicity of 2-dose primary series followed by booster.",
            "startOffset": 17989
        },
        {
            "endOffset": 18158,
            "sentence": "There was no statistical difference in incidence of fever >40 \u00b0C compared to PHiD-CV.",
            "startOffset": 18073
        },
        {
            "endOffset": 18233,
            "sentence": "All formulations were well-tolerated and appeared immunogenic in toddlers.",
            "startOffset": 18159
        }
    ],
    "bib_entries": {
        "bib0005": {
            "authors": [
                {
                    "first": "Joseph P.",
                    "initial": "J.P.",
                    "last": "Lynch"
                },
                {
                    "first": "George G.",
                    "initial": "G.G.",
                    "last": "Zhanel"
                }
            ],
            "doi": "10.1097/MCP.0b013e3283385653",
            "firstpage": "217",
            "issn": "10705287",
            "lastpage": "225",
            "pmid": "20375783",
            "pub_year": 2010,
            "title": "Streptococcus pneumoniae: Epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines",
            "volume": "16"
        },
        "bib0010": {
            "authors": [
                {
                    "first": "Katherine L.",
                    "initial": "K.L.",
                    "last": "O'Brien"
                },
                {
                    "first": "Lara J.",
                    "initial": "L.J.",
                    "last": "Wolfson"
                },
                {
                    "first": "James P.",
                    "initial": "J.P.",
                    "last": "Watt"
                },
                {
                    "first": "Emily",
                    "initial": "E.",
                    "last": "Henkle"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Deloria-Knoll"
                },
                {
                    "first": "Natalie",
                    "initial": "N.",
                    "last": "McCall"
                },
                {
                    "first": "Ellen",
                    "initial": "E.",
                    "last": "Lee"
                },
                {
                    "first": "Kim",
                    "initial": "K.",
                    "last": "Mulholland"
                },
                {
                    "first": "Orin S.",
                    "initial": "O.S.",
                    "last": "Levine"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Cherian"
                }
            ],
            "doi": "10.1016/S0140-6736(09)61204-6",
            "firstpage": "893",
            "issn": "01406736",
            "lastpage": "902",
            "pmid": "19748398",
            "pub_year": 2009,
            "title": "Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates",
            "volume": "374"
        },
        "bib0015": {
            "authors": [
                {
                    "first": "Carlos G.",
                    "initial": "C.G.",
                    "last": "Grijalva"
                },
                {
                    "first": "J. Pekka",
                    "initial": "J.P.",
                    "last": "Nuorti"
                },
                {
                    "first": "Patrick G.",
                    "initial": "P.G.",
                    "last": "Arbogast"
                },
                {
                    "first": "Stacey W.",
                    "initial": "S.W.",
                    "last": "Martin"
                },
                {
                    "first": "Kathryn M.",
                    "initial": "K.M.",
                    "last": "Edwards"
                },
                {
                    "first": "Marie R.",
                    "initial": "M.R.",
                    "last": "Griffin"
                }
            ],
            "doi": "10.1016/S0140-6736(07)60564-9",
            "firstpage": "1179",
            "issn": "01406736",
            "lastpage": "1186",
            "pmid": "17416262",
            "pub_year": 2007,
            "title": "Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis",
            "volume": "369"
        },
        "bib0020": {
            "authors": [
                {
                    "first": "Pierre Alex",
                    "initial": "P.A.",
                    "last": "Crisinel"
                },
                {
                    "first": "Isabelle",
                    "initial": "I.",
                    "last": "Chevalier"
                },
                {
                    "first": "Fabien",
                    "initial": "F.",
                    "last": "Rallu"
                },
                {
                    "first": "Bruce",
                    "initial": "B.",
                    "last": "Tapiero"
                },
                {
                    "first": "Val\u00e9rie",
                    "initial": "V.",
                    "last": "Lamarre"
                },
                {
                    "first": "Roseline",
                    "initial": "R.",
                    "last": "Thibault"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Ovetchkine"
                }
            ],
            "doi": "10.1007/s00431-010-1214-7",
            "firstpage": "1311",
            "issn": "03406199",
            "lastpage": "1315",
            "pub_year": 2010,
            "title": "Invasive pneumococcal disease after implementation of a reduced three-dose pneumococcal conjugate vaccine program: A pediatric tertiary care center experience",
            "volume": "169"
        },
        "bib0025": {
            "authors": [
                {
                    "first": "Tamara",
                    "initial": "T.",
                    "last": "Pilishvili"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Lexau"
                },
                {
                    "first": "Monica M.",
                    "initial": "M.M.",
                    "last": "Farley"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Hadler"
                },
                {
                    "first": "Lee H.",
                    "initial": "L.H.",
                    "last": "Harrison"
                },
                {
                    "first": "Nancy M.",
                    "initial": "N.M.",
                    "last": "Bennett"
                },
                {
                    "first": "Arthur",
                    "initial": "A.",
                    "last": "Reingold"
                },
                {
                    "first": "Ann",
                    "initial": "A.",
                    "last": "Thomas"
                },
                {
                    "first": "William",
                    "initial": "W.",
                    "last": "Schaffner"
                },
                {
                    "first": "Allen S.",
                    "initial": "A.S.",
                    "last": "Craig"
                },
                {
                    "first": "Philip J.",
                    "initial": "P.J.",
                    "last": "Smith"
                },
                {
                    "first": "Bernard W.",
                    "initial": "B.W.",
                    "last": "Beall"
                },
                {
                    "first": "Cynthia G.",
                    "initial": "C.G.",
                    "last": "Whitney"
                },
                {
                    "first": "Matthew R.",
                    "initial": "M.R.",
                    "last": "Moore"
                }
            ],
            "doi": "10.1086/648593",
            "firstpage": "32",
            "issn": "00221899",
            "lastpage": "41",
            "pmid": "19947881",
            "pub_year": 2010,
            "title": "Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine",
            "volume": "201"
        },
        "bib0030": {
            "authors": [
                {
                    "first": "Daniel M.",
                    "initial": "D.M.",
                    "last": "Weinberger"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Malley"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Lipsitch"
                }
            ],
            "doi": "10.1016/S0140-6736(10)62225-8",
            "firstpage": "1962",
            "issn": "01406736",
            "lastpage": "1973",
            "pmid": "21492929",
            "pub_year": 2011,
            "title": "Serotype replacement in disease after pneumococcal vaccination",
            "volume": "378"
        },
        "bib0035": {
            "authors": [
                {
                    "first": "Sheldon L.",
                    "initial": "S.L.",
                    "last": "Kaplan"
                },
                {
                    "first": "William J.",
                    "initial": "W.J.",
                    "last": "Barson"
                },
                {
                    "first": "Philana L.",
                    "initial": "P.L.",
                    "last": "Lin"
                },
                {
                    "first": "Stephanie H.",
                    "initial": "S.H.",
                    "last": "Stovall"
                },
                {
                    "first": "John S.",
                    "initial": "J.S.",
                    "last": "Bradley"
                },
                {
                    "first": "Tina Q.",
                    "initial": "T.Q.",
                    "last": "Tan"
                },
                {
                    "first": "Jill A.",
                    "initial": "J.A.",
                    "last": "Hoffman"
                },
                {
                    "first": "Laurence B.",
                    "initial": "L.B.",
                    "last": "Givner"
                },
                {
                    "first": "Edward O.",
                    "initial": "E.O.",
                    "last": "Mason"
                }
            ],
            "doi": "10.1542/peds.2008-1702",
            "firstpage": "429",
            "issn": "00314005",
            "lastpage": "436",
            "pmid": "20176669",
            "pub_year": 2010,
            "title": "Serotype 19A is the most common serotype causing invasive pneumococcal infections in children",
            "volume": "125"
        },
        "bib0040": {
            "authors": [
                {
                    "first": "Bernard",
                    "initial": "B.",
                    "last": "Beall"
                },
                {
                    "first": "M. Catherine",
                    "initial": "M.C.",
                    "last": "McEllistrem"
                },
                {
                    "first": "Robert E.",
                    "initial": "R.E.",
                    "last": "Gertz"
                },
                {
                    "first": "Stephanie",
                    "initial": "S.",
                    "last": "Wedel"
                },
                {
                    "first": "David J.",
                    "initial": "D.J.",
                    "last": "Boxrud"
                },
                {
                    "first": "Antonio L.",
                    "initial": "A.L.",
                    "last": "Gonzalez"
                },
                {
                    "first": "Marie Jo",
                    "initial": "M.J.",
                    "last": "Medina"
                },
                {
                    "first": "Rekha",
                    "initial": "R.",
                    "last": "Pai"
                },
                {
                    "first": "Terry A.",
                    "initial": "T.A.",
                    "last": "Thompson"
                },
                {
                    "first": "Lee H.",
                    "initial": "L.H.",
                    "last": "Harrison"
                },
                {
                    "first": "Lesley",
                    "initial": "L.",
                    "last": "McGee"
                },
                {
                    "first": "Cynthia G.",
                    "initial": "C.G.",
                    "last": "Whitney"
                }
            ],
            "doi": "10.1128/JCM.44.3.999-1017.2006",
            "firstpage": "999",
            "issn": "00951137",
            "lastpage": "1017",
            "pmid": "16517889",
            "pub_year": 2006,
            "title": "Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002",
            "volume": "44"
        },
        "bib0045": {
            "authors": [
                {
                    "first": "K. K.",
                    "initial": "K.K.",
                    "last": "Hsu"
                },
                {
                    "first": "J. E.",
                    "initial": "J.E.",
                    "last": "Kellenberg"
                },
                {
                    "first": "S. I.",
                    "initial": "S.I.",
                    "last": "Pelton"
                },
                {
                    "first": "D. S.",
                    "initial": "D.S.",
                    "last": "Friedman"
                },
                {
                    "first": "M. R.",
                    "initial": "M.R.",
                    "last": "Moore"
                },
                {
                    "first": "H. T.",
                    "initial": "H.T.",
                    "last": "Jordan"
                }
            ],
            "firstpage": "1077",
            "issn": "01492195",
            "lastpage": "1080",
            "pmid": "17947966",
            "pub_year": 2007,
            "title": "Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae - Massachusetts, 2001-2006",
            "volume": "56"
        },
        "bib0050": {
            "authors": [
                {
                    "first": "Grace M.",
                    "initial": "G.M.",
                    "last": "Lee"
                },
                {
                    "first": "Ken",
                    "initial": "K.",
                    "last": "Kleinman"
                },
                {
                    "first": "Stephen I.",
                    "initial": "S.I.",
                    "last": "Pelton"
                },
                {
                    "first": "William",
                    "initial": "W.",
                    "last": "Hanage"
                },
                {
                    "first": "Susan S.",
                    "initial": "S.S.",
                    "last": "Huang"
                },
                {
                    "first": "Matthew",
                    "initial": "M.",
                    "last": "Lakoma"
                },
                {
                    "first": "Maya",
                    "initial": "M.",
                    "last": "Dutta-Linn"
                },
                {
                    "first": "Nicholas J.",
                    "initial": "N.J.",
                    "last": "Croucher"
                },
                {
                    "first": "Abbie",
                    "initial": "A.",
                    "last": "Stevenson"
                },
                {
                    "first": "Jonathan A.",
                    "initial": "J.A.",
                    "last": "Finkelstein"
                }
            ],
            "doi": "10.1093/jpids/pit057",
            "firstpage": "23",
            "issn": "20487193",
            "lastpage": "32",
            "pub_year": 2014,
            "title": "Impact of 13-valent pneumococcal conjugate vaccination on Streptococcus pneumoniae carriage in young children in Massachusetts",
            "volume": "3"
        },
        "bib0055": {
            "authors": [
                {
                    "first": "Walter H.B.",
                    "initial": "W.H.B.",
                    "last": "Demczuk"
                },
                {
                    "first": "Irene",
                    "initial": "I.",
                    "last": "Martin"
                },
                {
                    "first": "Averil",
                    "initial": "A.",
                    "last": "Griffith"
                },
                {
                    "first": "Brigitte",
                    "initial": "B.",
                    "last": "Lefebvre"
                },
                {
                    "first": "Allison",
                    "initial": "A.",
                    "last": "McGeer"
                },
                {
                    "first": "Amanda",
                    "initial": "A.",
                    "last": "Shane"
                },
                {
                    "first": "George G.",
                    "initial": "G.G.",
                    "last": "Zhanel"
                },
                {
                    "first": "Gregory J.",
                    "initial": "G.J.",
                    "last": "Tyrrell"
                },
                {
                    "first": "Matthew W.",
                    "initial": "M.W.",
                    "last": "Gilmour"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Hoang"
                },
                {
                    "first": "Ingrid",
                    "initial": "I.",
                    "last": "Pocock"
                },
                {
                    "first": "Ana",
                    "initial": "A.",
                    "last": "Paccagnella"
                },
                {
                    "first": "Loretta",
                    "initial": "L.",
                    "last": "Janz"
                },
                {
                    "first": "Sultana",
                    "initial": "S.",
                    "last": "Mithan"
                },
                {
                    "first": "Tazim",
                    "initial": "T.",
                    "last": "Rahim"
                },
                {
                    "first": "Greg",
                    "initial": "G.",
                    "last": "Horsman"
                },
                {
                    "first": "Evelyn",
                    "initial": "E.",
                    "last": "Nagle"
                },
                {
                    "first": "Rosanne",
                    "initial": "R.",
                    "last": "Kitzul"
                },
                {
                    "first": "Jared",
                    "initial": "J.",
                    "last": "Bullard"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Van Caeseele"
                },
                {
                    "first": "Denise",
                    "initial": "D.",
                    "last": "Sitter"
                },
                {
                    "first": "Dylan",
                    "initial": "D.",
                    "last": "Pillai"
                },
                {
                    "first": "Jonathan",
                    "initial": "J.",
                    "last": "Gubbay"
                },
                {
                    "first": "Prasad",
                    "initial": "P.",
                    "last": "Rawte"
                },
                {
                    "first": "Michel",
                    "initial": "M.",
                    "last": "Couillard"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Haldane"
                },
                {
                    "first": "Alexander",
                    "initial": "A.",
                    "last": "Doroshenko"
                },
                {
                    "first": "Maryse",
                    "initial": "M.",
                    "last": "Thibeault"
                },
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Brisson"
                },
                {
                    "first": "Francine",
                    "initial": "F.",
                    "last": "Plourde"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Thibault"
                },
                {
                    "first": "Lewis",
                    "initial": "L.",
                    "last": "Abbott"
                },
                {
                    "first": "Melanie",
                    "initial": "M.",
                    "last": "Stace"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Delaney"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Turgeon"
                },
                {
                    "first": "Tammy",
                    "initial": "T.",
                    "last": "Mahaney"
                },
                {
                    "first": "Lei",
                    "initial": "L.",
                    "last": "Ang"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Sellers"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Robberts"
                },
                {
                    "first": "Sandra",
                    "initial": "S.",
                    "last": "March"
                },
                {
                    "first": "Cheryl",
                    "initial": "C.",
                    "last": "Case"
                },
                {
                    "first": "Rosalyn",
                    "initial": "R.",
                    "last": "Robertson"
                },
                {
                    "first": "Becky",
                    "initial": "B.",
                    "last": "Nash"
                },
                {
                    "first": "Chris",
                    "initial": "C.",
                    "last": "Cash"
                },
                {
                    "first": "Agron",
                    "initial": "A.",
                    "last": "Plevneshi"
                },
                {
                    "first": "Sylvia",
                    "initial": "S.",
                    "last": "Pong-Porter"
                },
                {
                    "first": "Karen",
                    "initial": "K.",
                    "last": "Green"
                },
                {
                    "first": "Kenny",
                    "initial": "K.",
                    "last": "Wong"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1139/W2012-073",
            "firstpage": "1008",
            "issn": "00084166",
            "lastpage": "1017",
            "pmid": "22827750",
            "pub_year": 2012,
            "title": "Serotype distribution of invasive Streptococcus pneumoniae in Canada during the introduction of the 13-valent pneumococcal conjugate vaccine, 2010",
            "volume": "58"
        },
        "bib0060": {
            "authors": [
                {
                    "first": "Sheldon L.",
                    "initial": "S.L.",
                    "last": "Kaplan"
                },
                {
                    "first": "William J.",
                    "initial": "W.J.",
                    "last": "Barson"
                },
                {
                    "first": "Philana Ling",
                    "initial": "P.L.",
                    "last": "Lin"
                },
                {
                    "first": "Jos\u00e9 R.",
                    "initial": "J.R.",
                    "last": "Romero"
                },
                {
                    "first": "John S.",
                    "initial": "J.S.",
                    "last": "Bradley"
                },
                {
                    "first": "Tina Q.",
                    "initial": "T.Q.",
                    "last": "Tan"
                },
                {
                    "first": "Jill A.",
                    "initial": "J.A.",
                    "last": "Hoffman"
                },
                {
                    "first": "Laurence B.",
                    "initial": "L.B.",
                    "last": "Givner"
                },
                {
                    "first": "Edward O.",
                    "initial": "E.O.",
                    "last": "Mason"
                }
            ],
            "doi": "10.1097/INF.0b013e318275614b",
            "firstpage": "203",
            "issn": "08913668",
            "lastpage": "207",
            "pmid": "23558320",
            "pub_year": 2013,
            "title": "Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine",
            "volume": "32"
        },
        "bib0065": {
            "authors": [
                {
                    "first": "Michael E.",
                    "initial": "M.E.",
                    "last": "Pichichero"
                },
                {
                    "first": "Ravinder",
                    "initial": "R.",
                    "last": "Kaur"
                },
                {
                    "first": "Janet R.",
                    "initial": "J.R.",
                    "last": "Casey"
                },
                {
                    "first": "Qingfu",
                    "initial": "Q.",
                    "last": "Xu"
                },
                {
                    "first": "Anthony",
                    "initial": "A.",
                    "last": "Almudevar"
                },
                {
                    "first": "Martina",
                    "initial": "M.",
                    "last": "Ochs"
                }
            ],
            "doi": "10.4161/hv.19820",
            "firstpage": "799",
            "issn": "2164554X",
            "lastpage": "805",
            "pmid": "22495112",
            "pub_year": 2012,
            "title": "Antibody response to Streptococcus pneumoniae proteins PhtD, LytB, PcpA, PhtE and Ply after nasopharyngeal colonization and acute otitis media in children",
            "volume": "8"
        },
        "bib0070": {
            "authors": [
                {
                    "first": "J. E.",
                    "initial": "J.E.",
                    "last": "Alexander"
                },
                {
                    "first": "R. A.",
                    "initial": "R.A.",
                    "last": "Lock"
                },
                {
                    "first": "C. C.A.M.",
                    "initial": "C.C.A.M.",
                    "last": "Peeters"
                },
                {
                    "first": "J. T.",
                    "initial": "J.T.",
                    "last": "Poolman"
                },
                {
                    "first": "P. W.",
                    "initial": "P.W.",
                    "last": "Andrew"
                },
                {
                    "first": "T. J.",
                    "initial": "T.J.",
                    "last": "Mitchell"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Hansman"
                },
                {
                    "first": "J. C.",
                    "initial": "J.C.",
                    "last": "Paton"
                }
            ],
            "firstpage": "5683",
            "issn": "00199567",
            "lastpage": "5688",
            "pmid": "7960154",
            "pub_year": 1994,
            "title": "Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae",
            "volume": "62"
        },
        "bib0075": {
            "authors": [
                {
                    "first": "A. D.",
                    "initial": "A.D.",
                    "last": "Ogunniyi"
                },
                {
                    "first": "M. C.",
                    "initial": "M.C.",
                    "last": "Woodrow"
                },
                {
                    "first": "J. T.",
                    "initial": "J.T.",
                    "last": "Poolman"
                },
                {
                    "first": "J. C.",
                    "initial": "J.C.",
                    "last": "Paton"
                }
            ],
            "doi": "10.1128/IAI.69.10.5997-6003.2001",
            "firstpage": "5997",
            "issn": "00199567",
            "lastpage": "6003",
            "pmid": "11553536",
            "pub_year": 2001,
            "title": "Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA",
            "volume": "69"
        },
        "bib0080": {
            "authors": [
                {
                    "first": "Mar\u00eda",
                    "initial": "M.",
                    "last": "Del Mar Garc\u00eda-Su\u00e1rez"
                },
                {
                    "first": "Mar\u00eda Dolores",
                    "initial": "M.D.",
                    "last": "Cima-Cabal"
                },
                {
                    "first": "Noelia",
                    "initial": "N.",
                    "last": "Fl\u00f3rez"
                },
                {
                    "first": "Pilar",
                    "initial": "P.",
                    "last": "Garc\u00eda"
                },
                {
                    "first": "Rafael",
                    "initial": "R.",
                    "last": "Cernuda-Cernuda"
                },
                {
                    "first": "Aurora",
                    "initial": "A.",
                    "last": "Astudillo"
                },
                {
                    "first": "Fernando",
                    "initial": "F.",
                    "last": "V\u00e1zquez"
                },
                {
                    "first": "Juan R.",
                    "initial": "J.R.",
                    "last": "De Los Toyos"
                },
                {
                    "first": "F. Javier",
                    "initial": "F.J.",
                    "last": "M\u00e9ndez"
                }
            ],
            "doi": "10.1128/IAI.72.8.4534-4540.2004",
            "firstpage": "4534",
            "issn": "00199567",
            "lastpage": "4540",
            "pmid": "15271913",
            "pub_year": 2004,
            "title": "Protection against pneumococcal pneumonia in mice by monoclonal antibodies to pneumolysin",
            "volume": "72"
        },
        "bib0085": {
            "authors": [
                {
                    "first": "Fabrice",
                    "initial": "F.",
                    "last": "Godfroid"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Hermand"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Verlant"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Deno\u00ebl"
                },
                {
                    "first": "Jan T.",
                    "initial": "J.T.",
                    "last": "Poolman"
                }
            ],
            "doi": "10.1128/IAI.00378-10",
            "firstpage": "238",
            "issn": "00199567",
            "lastpage": "245",
            "pmid": "20956575",
            "pub_year": 2011,
            "title": "Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens",
            "volume": "79"
        },
        "bib0090": {
            "authors": [
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Deno\u00ebl"
                },
                {
                    "first": "Mario T.",
                    "initial": "M.T.",
                    "last": "Philipp"
                },
                {
                    "first": "Lara",
                    "initial": "L.",
                    "last": "Doyle"
                },
                {
                    "first": "Dale",
                    "initial": "D.",
                    "last": "Martin"
                },
                {
                    "first": "Georges",
                    "initial": "G.",
                    "last": "Carletti"
                },
                {
                    "first": "Jan T.",
                    "initial": "J.T.",
                    "last": "Poolman"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.05.051",
            "firstpage": "5495",
            "issn": "0264410X",
            "lastpage": "5501",
            "pmid": "21624422",
            "pub_year": 2011,
            "title": "A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae",
            "volume": "29"
        },
        "bib0095": null,
        "bib0100": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1586/erv.09.113",
            "firstpage": "1479",
            "issn": "14760584",
            "lastpage": "1500",
            "pmid": "19863240",
            "pub_year": 2009,
            "title": "10-Valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix\u2122",
            "volume": "8"
        },
        "bib0105": {
            "authors": [
                {
                    "first": "J. W.A.",
                    "initial": "J.W.A.",
                    "last": "Findlay"
                },
                {
                    "first": "W. C.",
                    "initial": "W.C.",
                    "last": "Smith"
                },
                {
                    "first": "J. W.",
                    "initial": "J.W.",
                    "last": "Lee"
                },
                {
                    "first": "G. D.",
                    "initial": "G.D.",
                    "last": "Nordblom"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Das"
                },
                {
                    "first": "B. S.",
                    "initial": "B.S.",
                    "last": "Desilva"
                },
                {
                    "first": "M. N.",
                    "initial": "M.N.",
                    "last": "Khan"
                },
                {
                    "first": "R. R.",
                    "initial": "R.R.",
                    "last": "Bowsher"
                }
            ],
            "doi": "10.1016/S0731-7085(99)00244-7",
            "firstpage": "1249",
            "issn": "07317085",
            "lastpage": "1273",
            "pmid": "10708409",
            "pub_year": 2000,
            "title": "Validation of immunoassays for bioanalysis: A pharmaceutical industry perspective",
            "volume": "21"
        },
        "bib0110": {
            "authors": [
                {
                    "first": "Jan T.",
                    "initial": "J.T.",
                    "last": "Poolman"
                },
                {
                    "first": "Carl E.",
                    "initial": "C.E.",
                    "last": "Frasch"
                },
                {
                    "first": "Helena",
                    "initial": "H.",
                    "last": "K\u00e4yhty"
                },
                {
                    "first": "Pascal",
                    "initial": "P.",
                    "last": "Lestrate"
                },
                {
                    "first": "Shabir A.",
                    "initial": "S.A.",
                    "last": "Madhi"
                },
                {
                    "first": "Isabelle",
                    "initial": "I.",
                    "last": "Henckaerts"
                }
            ],
            "doi": "10.1128/CVI.00289-09",
            "firstpage": "134",
            "issn": "15566811",
            "lastpage": "142",
            "pmid": "19889940",
            "pub_year": 2010,
            "title": "Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines",
            "volume": "17"
        },
        "bib0115": {
            "authors": [
                {
                    "first": "Isabelle",
                    "initial": "I.",
                    "last": "Henckaerts"
                },
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Durant"
                },
                {
                    "first": "Dany",
                    "initial": "D.",
                    "last": "De Grave"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Poolman"
                }
            ],
            "doi": "10.1016/j.vaccine.2006.09.029",
            "firstpage": "2518",
            "issn": "0264410X",
            "lastpage": "2527",
            "pmid": "17034907",
            "pub_year": 2007,
            "title": "Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children",
            "volume": "25"
        },
        "bib0120": {
            "authors": [
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Seiberling"
                },
                {
                    "first": "Monica",
                    "initial": "M.",
                    "last": "Bologa"
                },
                {
                    "first": "Roger",
                    "initial": "R.",
                    "last": "Brookes"
                },
                {
                    "first": "Martina",
                    "initial": "M.",
                    "last": "Ochs"
                },
                {
                    "first": "Kerry",
                    "initial": "K.",
                    "last": "Go"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Neveu"
                },
                {
                    "first": "Thierry",
                    "initial": "T.",
                    "last": "Kamtchoua"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Lashley"
                },
                {
                    "first": "Tao",
                    "initial": "T.",
                    "last": "Yuan"
                },
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Gurunathan"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.10.080",
            "firstpage": "7455",
            "issn": "0264410X",
            "lastpage": "7460",
            "pmid": "23131206",
            "pub_year": 2012,
            "title": "Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults",
            "volume": "30"
        },
        "bib0125": {
            "authors": [
                {
                    "first": "Monica",
                    "initial": "M.",
                    "last": "Bologa"
                },
                {
                    "first": "Thierry",
                    "initial": "T.",
                    "last": "Kamtchoua"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Hopfer"
                },
                {
                    "first": "Xiaohua",
                    "initial": "X.",
                    "last": "Sheng"
                },
                {
                    "first": "Bryony",
                    "initial": "B.",
                    "last": "Hicks"
                },
                {
                    "first": "Garvin",
                    "initial": "G.",
                    "last": "Bixler"
                },
                {
                    "first": "Victor",
                    "initial": "V.",
                    "last": "Hou"
                },
                {
                    "first": "Vildana",
                    "initial": "V.",
                    "last": "Pehlic"
                },
                {
                    "first": "Tao",
                    "initial": "T.",
                    "last": "Yuan"
                },
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Gurunathan"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.10.076",
            "firstpage": "7461",
            "issn": "0264410X",
            "lastpage": "7468",
            "pmid": "23123106",
            "pub_year": 2012,
            "title": "Safety and immunogenicity of pneumococcal protein vaccine candidates: Monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine",
            "volume": "30"
        },
        "bib0130": {
            "authors": [
                {
                    "first": "Thierry",
                    "initial": "T.",
                    "last": "Kamtchoua"
                },
                {
                    "first": "Monica",
                    "initial": "M.",
                    "last": "Bologa"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Hopfer"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Neveu"
                },
                {
                    "first": "Branda",
                    "initial": "B.",
                    "last": "Hu"
                },
                {
                    "first": "Xiaohua",
                    "initial": "X.",
                    "last": "Sheng"
                },
                {
                    "first": "Nicolas",
                    "initial": "N.",
                    "last": "Corde"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Pouzet"
                },
                {
                    "first": "Gloria",
                    "initial": "G.",
                    "last": "Zimmermann"
                },
                {
                    "first": "Sanjay",
                    "initial": "S.",
                    "last": "Gurunathan"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.11.005",
            "firstpage": "327",
            "issn": "0264410X",
            "lastpage": "333",
            "pmid": "23153437",
            "pub_year": 2013,
            "title": "Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults",
            "volume": "31"
        },
        "bib0135": {
            "authors": [
                {
                    "first": "Sharad K.",
                    "initial": "S.K.",
                    "last": "Sharma"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Roumanes"
                },
                {
                    "first": "Anthony",
                    "initial": "A.",
                    "last": "Almudevar"
                },
                {
                    "first": "Tim R.",
                    "initial": "T.R.",
                    "last": "Mosmann"
                },
                {
                    "first": "Michael E.",
                    "initial": "M.E.",
                    "last": "Pichichero"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.03.060",
            "firstpage": "3090",
            "issn": "0264410X",
            "lastpage": "3097",
            "pmid": "23632305",
            "pub_year": 2013,
            "title": "CD4+ T-cell responses among adults and young children in response to Streptococcus pneumoniae and Haemophilus influenzae vaccine candidate protein antigens",
            "volume": "31"
        },
        "bib0140": {
            "authors": [
                {
                    "first": "Satu",
                    "initial": "S.",
                    "last": "Rapola"
                },
                {
                    "first": "Virva",
                    "initial": "V.",
                    "last": "Jantti"
                },
                {
                    "first": "Raili",
                    "initial": "R.",
                    "last": "Haikala"
                },
                {
                    "first": "Ritva",
                    "initial": "R.",
                    "last": "Syrjanen"
                },
                {
                    "first": "George M.",
                    "initial": "G.M.",
                    "last": "Carlone"
                },
                {
                    "first": "Jacquelyn S.",
                    "initial": "J.S.",
                    "last": "Sampson"
                },
                {
                    "first": "David E.",
                    "initial": "D.E.",
                    "last": "Briles"
                },
                {
                    "first": "James C.",
                    "initial": "J.C.",
                    "last": "Paton"
                },
                {
                    "first": "Aino K.",
                    "initial": "A.K.",
                    "last": "Takala"
                },
                {
                    "first": "Terhi M.",
                    "initial": "T.M.",
                    "last": "Kilpi"
                },
                {
                    "first": "Helena",
                    "initial": "H.",
                    "last": "Kayhty"
                }
            ],
            "doi": "10.1086/315822",
            "firstpage": "1146",
            "issn": "00221899",
            "lastpage": "1152",
            "pmid": "10979911",
            "pub_year": 2000,
            "title": "Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media",
            "volume": "182"
        },
        "bib0145": {
            "authors": [
                {
                    "first": "Emma",
                    "initial": "E.",
                    "last": "Holmlund"
                },
                {
                    "first": "Beatriz",
                    "initial": "B.",
                    "last": "Quiambao"
                },
                {
                    "first": "Jukka",
                    "initial": "J.",
                    "last": "Ollgren"
                },
                {
                    "first": "Teija",
                    "initial": "T.",
                    "last": "Jaakkola"
                },
                {
                    "first": "C\u00e9cile",
                    "initial": "C.",
                    "last": "Neyt"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Poolman"
                },
                {
                    "first": "Hanna",
                    "initial": "H.",
                    "last": "Nohynek"
                },
                {
                    "first": "Helena",
                    "initial": "H.",
                    "last": "K\u00e4yhty"
                }
            ],
            "doi": "10.1128/CVI.00050-09",
            "firstpage": "916",
            "issn": "15566811",
            "lastpage": "923",
            "pmid": "19403781",
            "pub_year": 2009,
            "title": "Antibodies to pneumococcal proteins PhtD, CbpA, and LytC in filipino pregnant women and their infants in relation to pneumococcal carriage",
            "volume": "16"
        },
        "bib0150": {
            "authors": [
                {
                    "first": "Emma",
                    "initial": "E.",
                    "last": "Holmlund"
                },
                {
                    "first": "Beatriz",
                    "initial": "B.",
                    "last": "Quiambao"
                },
                {
                    "first": "Jukka",
                    "initial": "J.",
                    "last": "Ollgren"
                },
                {
                    "first": "Hanna",
                    "initial": "H.",
                    "last": "Nohynek"
                },
                {
                    "first": "Helena",
                    "initial": "H.",
                    "last": "K\u00e4yhty"
                }
            ],
            "doi": "10.1016/j.vaccine.2005.07.055",
            "firstpage": "57",
            "issn": "0264410X",
            "lastpage": "65",
            "pmid": "16115703",
            "pub_year": 2006,
            "title": "Development of natural antibodies to pneumococcal surface protein A, pneumococcal surface adhesin a and pneumolysin in Filipino pregnant women and their infants in relation to pneumococcal carriage",
            "volume": "24"
        },
        "bib0155": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Pascal",
                    "initial": "P.",
                    "last": "Peeters"
                },
                {
                    "first": "Viktor",
                    "initial": "V.",
                    "last": "Chrobok"
                },
                {
                    "first": "Pavla",
                    "initial": "P.",
                    "last": "Kriz"
                },
                {
                    "first": "Elena",
                    "initial": "E.",
                    "last": "Novakova"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Kaliskova"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Kohl"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Lommel"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Poolman"
                },
                {
                    "first": "Jean Paul",
                    "initial": "J.P.",
                    "last": "Prieels"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1016/S0140-6736(06)68304-9",
            "firstpage": "740",
            "issn": "01406736",
            "lastpage": "748",
            "pmid": "16517274",
            "pub_year": 2006,
            "title": "Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: A randomised double-blind efficacy study",
            "volume": "367"
        },
        "bib0160": {
            "authors": [
                {
                    "first": "Amy Sarah",
                    "initial": "A.S.",
                    "last": "Ginsburg"
                },
                {
                    "first": "Moon H.",
                    "initial": "M.H.",
                    "last": "Nahm"
                },
                {
                    "first": "Farukh M.",
                    "initial": "F.M.",
                    "last": "Khambaty"
                },
                {
                    "first": "Mark R.",
                    "initial": "M.R.",
                    "last": "Alderson"
                }
            ],
            "doi": "10.1586/erv.12.5",
            "firstpage": "279",
            "issn": "14760584",
            "lastpage": "285",
            "pmid": "22380821",
            "pub_year": 2012,
            "title": "Issues and challenges in the development of pneumococcal protein vaccines",
            "volume": "11"
        }
    },
    "body_text": [
        {
            "endOffset": 26930,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0030",
            "sentence": "Antibodies were quantified using an in-house multiplex assay coated with protein D (PD), non-detoxified pneumolysin (Ply) and PhtD, with a cut-off of 112 LU/mL for PD, 599 LU/mL for Ply and 391 LU/mL for PhtD.",
            "startOffset": 26721,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 44180,
            "parents": [],
            "secId": "sec0080",
            "sentence": "All authors critically reviewed the different drafts of the manuscript and approved the final version.",
            "startOffset": 44078,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 25782,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0020",
            "sentence": "All vaccines were manufactured by GlaxoSmithKline Vaccines.",
            "startOffset": 25723,
            "title": "Participants and vaccines"
        },
        {
            "endOffset": 31696,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "Specific grade 3 solicited local symptoms were reported for 0.0\u20139.6% of investigational vaccine recipients and for 0.0\u20136.0% of PHiD-CV recipients (Fig. 2).",
            "startOffset": 31541,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 29697,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0035",
            "sentence": "Analyses were performed with Statistical Analysis System (SAS\u00ae Institute Inc., Cary, NC).",
            "startOffset": 29608,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 42629,
            "parents": [],
            "secId": "sec0070",
            "sentence": "This lower number of participants could have limited the probability of detecting a potential significant difference in the incidence of grade 3 fever.",
            "startOffset": 42478,
            "title": "Discussion"
        },
        {
            "endOffset": 30310,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0045",
            "sentence": "Most toddlers (98.8%) were of white-Caucasian/European heritage and 50.6% were male.",
            "startOffset": 30226,
            "title": "Study participants and demographics"
        },
        {
            "endOffset": 40007,
            "parents": [],
            "secId": "sec0070",
            "sentence": "A different immune response in adults and toddlers was also observed in a study that characterized circulating antigen-specific CD4+ T cells responsive to six pneumococcal protein antigens (including PhtD and Ply).",
            "startOffset": 39793,
            "title": "Discussion"
        },
        {
            "endOffset": 34818,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0060",
            "sentence": "In the groups receiving pneumococcal protein-containing formulations, antibody GMCs increased 8.5\u201316.3-fold for anti-PhtD antibodies and 8.2\u201354.2-fold for anti-Ply antibodies from pre-vaccination to post-dose 2.",
            "startOffset": 34607,
            "title": "Immune response to pneumococcal proteins PhtD and Ply"
        },
        {
            "endOffset": 37716,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "Post-booster, seropositivity rates increased to 97.6\u2013100% of toddlers.",
            "startOffset": 37646,
            "title": "Immune response to pneumococcal serotype-specific PS-conjugates and to protein D"
        },
        {
            "endOffset": 33886,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0060",
            "sentence": "Pre-dose 1, 61.0\u201375.6% of toddlers in each group were seropositive for PhtD (antibody concentration \u2265391 LU/mL).",
            "startOffset": 33774,
            "title": "Immune response to pneumococcal proteins PhtD and Ply"
        },
        {
            "endOffset": 22329,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Another approach, different from multivalent conjugate vaccines, involves the use of highly conserved pneumococcal proteins.",
            "startOffset": 22205,
            "title": "Introduction"
        },
        {
            "endOffset": 42945,
            "parents": [],
            "secId": "sec0070",
            "sentence": "To conclude, this study showed that the investigational vaccines containing pneumococcal dPly and PhtD proteins were well-tolerated and immunogenic in toddlers.",
            "startOffset": 42785,
            "title": "Discussion"
        },
        {
            "endOffset": 25670,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0020",
            "sentence": "All investigational vaccines were adjuvanted with aluminum phosphate.",
            "startOffset": 25601,
            "title": "Participants and vaccines"
        },
        {
            "endOffset": 27093,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "bib0105": {
                    "endOffset": 26998,
                    "startOffset": 26994
                }
            },
            "secId": "sec0030",
            "sentence": "These cut-offs were based on the lower limit of quantification [21], the global variability of the assay at the highest dilution and the lower limit of linearity.",
            "startOffset": 26931,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 38641,
            "parents": [],
            "secId": "sec0070",
            "sentence": "The protein-only formulations tended to be more immunogenic than the formulations combining the proteins with PS-conjugates, both in primary and booster vaccination.",
            "startOffset": 38476,
            "title": "Discussion"
        },
        {
            "endOffset": 41741,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Development of these functional assays will be important to establish potential correlates of protection for the protein components.",
            "startOffset": 41609,
            "title": "Discussion"
        },
        {
            "endOffset": 26035,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0025",
            "sentence": "Solicited and unsolicited adverse events (AEs) were recorded by the participant's parents in paper diary cards that were returned to the investigator at the next study visit.",
            "startOffset": 25861,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 43924,
            "parents": [],
            "secId": "sec0080",
            "sentence": "R.P. and P.P. coordinated the clinical aspects of the study.",
            "startOffset": 43864,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 30079,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0045",
            "sentence": "Demographic characteristics were similar between groups.",
            "startOffset": 30023,
            "title": "Study participants and demographics"
        },
        {
            "endOffset": 29118,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0035",
            "sentence": "Incidences of local and general solicited symptoms and unsolicited AEs were calculated with exact 95% CIs after each vaccine dose and for overall primary doses, according to the type of symptom, intensity and relationship to vaccination.",
            "startOffset": 28881,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 38796,
            "parents": [],
            "secId": "sec0070",
            "sentence": "As no immunological correlates of protection have yet been established for the pneumococcal proteins, the clinical relevance of this finding is not known.",
            "startOffset": 38642,
            "title": "Discussion"
        },
        {
            "endOffset": 36230,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "Post-booster, for each vaccine serotype, these percentages were at least 97.9% in the PHiD-CV/dPly/PhtD groups except 6B (\u226589.4%), and at least 97.5% in the PHiD-CV group except 6B (95.0%).",
            "startOffset": 36041,
            "title": "Immune response to pneumococcal serotype-specific PS-conjugates and to protein D"
        },
        {
            "endOffset": 33498,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "Overall, 23 SAEs were reported in 17 toddlers (five, dPly/PhtD-10; three, dPly/PhtD-30; five, PHiD-CV/dPly/PhtD-10; four, PHiD-CV).",
            "startOffset": 33367,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 36842,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "For each vaccine serotype, at least 42.9% of PHiD-CV/dPly/PhtD recipients and at least 52.9% of PHiD-CV recipients had OPA titers \u22658 before booster vaccination.",
            "startOffset": 36682,
            "title": "Immune response to pneumococcal serotype-specific PS-conjugates and to protein D"
        },
        {
            "endOffset": 43666,
            "parents": [],
            "secId": "sec0075",
            "sentence": "P.P. declares he received payment for board membership, preparation of educational presentations and attending meetings from GlaxoSmithKline group of companies and other vaccine manufacturers, and his institution received grants from GlaxoSmithKline group of companies.",
            "startOffset": 43397,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 26721,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0030",
            "sentence": "Serum samples were stored at \u221220 \u00b0C until analysis at GlaxoSmithKline's laboratory, Rixensart, Belgium and SGS laboratory, Wavre, Belgium.",
            "startOffset": 26583,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 31290,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "Pain and redness were the most common solicited local symptoms after both primary doses (Fig. 2).",
            "startOffset": 31193,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 43842,
            "parents": [],
            "secId": "sec0075",
            "sentence": "J.U.R. was and M.T., and D.B. are employees of GlaxoSmithKline group of companies; J.U.R. and D.B. declare stock/share options ownership in GlaxoSmithKline group of companies.",
            "startOffset": 43667,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 44450,
            "parents": [],
            "secId": "sec0085",
            "sentence": "GlaxoSmithKline Biologicals SA also took responsibility for all costs associated with the development and publishing of the present manuscript.",
            "startOffset": 44307,
            "title": "Funding"
        },
        {
            "endOffset": 28249,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0035",
            "sentence": "To assess the impact of each protein formulation on the incidence of grade 3 fever (primary objective), the dPly/PhtD-10 and dPly/PhtD-30 groups were pooled, as were the PHiD-CV/dPly/PhtD-10 and PHiD-CV/dPly/PhtD-30 groups, and group differences (pooled dPly/PhtD minus PHiD-CV or pooled PHiD-CV/dPly/PhtD minus PHiD-CV) were calculated.",
            "startOffset": 27912,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 21892,
            "parents": [],
            "refoffsets": {
                "bib0035": {
                    "endOffset": 21825,
                    "startOffset": 21820
                },
                "bib0040": {
                    "endOffset": 21825,
                    "startOffset": 21820
                },
                "bib0045": {
                    "endOffset": 21825,
                    "startOffset": 21820
                }
            },
            "secId": "sec0005",
            "sentence": "Additionally, an increase in serotype 19A invasive pneumococcal disease (IPD) has been observed in some countries, partly due to multiple antibiotic resistance of this serotype [7\u20139] and no effective control after the introduction of a 7-valent PCV.",
            "startOffset": 21643,
            "title": "Introduction"
        },
        {
            "endOffset": 23292,
            "parents": [],
            "secId": "sec0005",
            "sentence": "The primary objective of this study focused on the incidence of grade 3 fever (rectal temperature >40 \u00b0C), as febrile reactions are common post-vaccination adverse reactions in children that have consequences for parents and healthcare providers, especially in terms of the resulting risk of febrile seizure.",
            "startOffset": 22984,
            "title": "Introduction"
        },
        {
            "endOffset": 24202,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0015",
            "sentence": "Written informed consent was obtained from the parents or legally acceptable representative of each child before enrolment.",
            "startOffset": 24079,
            "title": "Study design and objectives"
        },
        {
            "endOffset": 42785,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Nevertheless, the upper limits of the group difference CIs were below 10% and the primary objective was thus reached, despite the lower power of the study.",
            "startOffset": 42630,
            "title": "Discussion"
        },
        {
            "endOffset": 25600,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0020",
            "sentence": "Two further groups received a formulation containing the PS-conjugates of PHiD-CV (serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) and 10 or 30 \u03bcg of each dPly and PhtD (PHiD-CV/dPly/PhtD-10 and PHiD-CV/dPly/PhtD-30).",
            "startOffset": 25378,
            "title": "Participants and vaccines"
        },
        {
            "endOffset": 30225,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0045",
            "sentence": "The mean age in the TVC was 16.8 \u00b1 3.9 months at dose 1 (range: 12\u201324 months) and 23.2 \u00b1 4.0 months at booster vaccination (range: 17\u201330 months).",
            "startOffset": 30080,
            "title": "Study participants and demographics"
        },
        {
            "endOffset": 32831,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "All resolved completely within maximum two days.",
            "startOffset": 32783,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 25086,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0020",
            "sentence": "The study comprised five visits at study months 0 (dose 1), 2 (dose 2), 3 (post-primary), 6 (pre-booster) and 7 (post-booster).",
            "startOffset": 24959,
            "title": "Participants and vaccines"
        },
        {
            "endOffset": 34607,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0060",
            "sentence": "In the PHiD-CV group, seropositivity rates ranged from 87.5% to 90.2% at one month post-dose 2, pre-booster and one month post-booster (Table 2).",
            "startOffset": 34462,
            "title": "Immune response to pneumococcal proteins PhtD and Ply"
        },
        {
            "endOffset": 26582,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0030",
            "sentence": "Blood samples were collected pre-vaccination, one month post-dose 2, and pre- and one month post-booster.",
            "startOffset": 26477,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 21642,
            "parents": [],
            "refoffsets": {
                "bib0020": {
                    "endOffset": 21641,
                    "startOffset": 21636
                },
                "bib0025": {
                    "endOffset": 21641,
                    "startOffset": 21636
                },
                "bib0030": {
                    "endOffset": 21641,
                    "startOffset": 21636
                }
            },
            "secId": "sec0005",
            "sentence": "However, shifts in serotype epidemiology have been noted [4\u20136].",
            "startOffset": 21579,
            "title": "Introduction"
        },
        {
            "endOffset": 37451,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "Before vaccination, 19.5\u201331.8% of PS-conjugate recipients were seropositive for anti-PD antibodies.",
            "startOffset": 37352,
            "title": "Immune response to pneumococcal serotype-specific PS-conjugates and to protein D"
        },
        {
            "endOffset": 36040,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "Before booster vaccination, for each vaccine serotype, at least 92.5% of PHiD-CV/dPly/PhtD recipients and at least 95.0% of PHiD-CV recipients had antibody concentrations \u22650.2 \u03bcg/mL, except for serotypes 6B (\u226575.0% and \u226577.5%, respectively) and 23F (\u226587.8% and \u226592.5%).",
            "startOffset": 35771,
            "title": "Immune response to pneumococcal serotype-specific PS-conjugates and to protein D"
        },
        {
            "endOffset": 29416,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0035",
            "sentence": "Descriptive immunogenicity analyses were performed on the according-to-protocol (ATP) cohort for immunogenicity, comprising vaccinated toddlers who met all eligibility criteria, complied with the protocol-defined procedures and intervals, and with results for at least one antibody assay available.",
            "startOffset": 29118,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 41533,
            "parents": [],
            "refoffsets": {
                "bib0130": {
                    "endOffset": 41489,
                    "startOffset": 41485
                }
            },
            "secId": "sec0070",
            "sentence": "A toxin neutralization assay to measure functional activity of antibodies against Ply has already been reported, and antibody levels elicited by a dPly-containing vaccine were found to correlate with neutralizing activity [26], but a standardized assay is not available.",
            "startOffset": 41263,
            "title": "Discussion"
        },
        {
            "endOffset": 29607,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0035",
            "sentence": "ELISA geometric mean concentrations (GMCs) and OPA geometric mean titers (GMTs) with 95% CIs and seropositivity rates with exact 95% CIs were determined for each vaccine serotype or antigen.",
            "startOffset": 29417,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 31540,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "Post-booster, pain was the most common solicited local symptom for most groups (Fig. 2).",
            "startOffset": 31452,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 32081,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "One or more solicited general symptoms were reported for up to 59.6% of participants post-dose 1, 47.1% post-dose 2 and 50.0% post-booster in the investigational groups, and for up to 51.0% post-dose 1, 54.0% post-dose 2 and 38.0% post-booster in the PHiD-CV group (Fig. 3).",
            "startOffset": 31807,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 40603,
            "parents": [],
            "secId": "sec0070",
            "sentence": "There was a high level of baseline seropositivity for antibodies against PhtD and Ply in toddlers.",
            "startOffset": 40505,
            "title": "Discussion"
        },
        {
            "endOffset": 37006,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "Post-booster, these percentages increased to at least 89.2% in the PHiD-CV/dPly/PhtD groups (except 6B: \u226584.8%) and at least 94.6% in the PHiD-CV group (Table S3).",
            "startOffset": 36843,
            "title": "Immune response to pneumococcal serotype-specific PS-conjugates and to protein D"
        },
        {
            "endOffset": 33699,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "None of the SAEs were fatal or considered by the investigators to be vaccine-related; all resolved without sequelae except one (type 1 diabetes mellitus), which was improving at the time of study end.",
            "startOffset": 33499,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 43954,
            "parents": [],
            "secId": "sec0080",
            "sentence": "R.P. and P.P. collected data.",
            "startOffset": 43925,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 23690,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0015",
            "sentence": "The primary objective was to assess the incidence of fever >40.0 \u00b0C (rectal temperature) within seven days following at least one primary dose of the investigational vaccine compared to PHiD-CV.",
            "startOffset": 23496,
            "title": "Study design and objectives"
        },
        {
            "endOffset": 24369,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0015",
            "sentence": "A protocol summary is available at http://www.gsk-clinicalstudyregister.com (study ID: 113171).",
            "startOffset": 24274,
            "title": "Study design and objectives"
        },
        {
            "endOffset": 35592,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "One month post-dose 2, for each vaccine serotype, at least 97.5% of toddlers receiving a PHiD-CV/dPly/PhtD formulation had antibody concentrations \u22650.2 \u03bcg/mL, except for serotypes 6B (\u226578.3%) and 23F (\u226589.7%); for PHiD-CV recipients, at least 97.6% had antibody concentrations \u22650.2 \u03bcg/mL except for serotypes 6B (85.4%) and 23F (92.7%).",
            "startOffset": 35256,
            "title": "Immune response to pneumococcal serotype-specific PS-conjugates and to protein D"
        },
        {
            "endOffset": 22534,
            "parents": [],
            "refoffsets": {
                "bib0065": {
                    "endOffset": 22478,
                    "startOffset": 22474
                },
                "bib0070": {
                    "endOffset": 22533,
                    "startOffset": 22526
                },
                "bib0075": {
                    "endOffset": 22533,
                    "startOffset": 22526
                },
                "bib0080": {
                    "endOffset": 22533,
                    "startOffset": 22526
                },
                "bib0085": {
                    "endOffset": 22533,
                    "startOffset": 22526
                },
                "bib0090": {
                    "endOffset": 22533,
                    "startOffset": 22526
                }
            },
            "secId": "sec0005",
            "sentence": "Pneumolysin toxoid (dPly) and histidine-triad protein D (PhtD) are potential candidates that have been shown to play a role in natural exposure [13] and induce disease protection in animal models [14\u201318].",
            "startOffset": 22330,
            "title": "Introduction"
        },
        {
            "endOffset": 27546,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "bib0110": {
                    "endOffset": 27545,
                    "startOffset": 27541
                }
            },
            "secId": "sec0030",
            "sentence": "An antibody concentration of 0.2 \u03bcg/mL measured by the 22F-ELISA is equivalent to the antibody concentration of 0.35 \u03bcg/mL measured by the non-22F ELISA of the World Health Organization reference laboratory [22].",
            "startOffset": 27334,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 22983,
            "parents": [],
            "refoffsets": {
                "bib0095": {
                    "endOffset": 22982,
                    "startOffset": 22978
                }
            },
            "secId": "sec0005",
            "sentence": "In healthy adults, these formulations were well-tolerated and appeared immunogenic [19].",
            "startOffset": 22895,
            "title": "Introduction"
        },
        {
            "endOffset": 23979,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0015",
            "sentence": "The study protocol was reviewed and approved by the Ethics Committee for Multicentre Clinical Trials of Faculty Hospital Hradec Kralove and local hospital ethics committees.",
            "startOffset": 23806,
            "title": "Study design and objectives"
        },
        {
            "endOffset": 34979,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0060",
            "sentence": "One month post-booster, antibody GMCs for both PhtD and Ply were 2.2\u20133.2-fold higher than pre-booster and 1.4\u20132.2-fold higher than post-dose 2 (Tables 1 and 2).",
            "startOffset": 34819,
            "title": "Immune response to pneumococcal proteins PhtD and Ply"
        },
        {
            "endOffset": 43126,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Synflorix is a trademark of the GlaxoSmithKline group of companies.",
            "startOffset": 43059,
            "title": "Discussion"
        },
        {
            "endOffset": 42477,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Another limitation of the current study is the lower number of enrolled toddlers than planned (51 or 52 per group, instead of 60), because of increasing difficulty to find eligible children due to inclusion of the PCV vaccines in the Czech universal mass vaccination program, and a lower acceptance of vaccines by the parents after the H1N1 pandemic and due to anti-vaccination movements.",
            "startOffset": 42089,
            "title": "Discussion"
        },
        {
            "endOffset": 30609,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "Post-dose 1, grade 3 fever was reported for one toddler in the pooled dPly/PhtD group and one toddler in the pooled PHiD-CV/dPly/PhtD group; no grade 3 fever was reported for toddlers in the PHiD-CV group (difference in rates, for each comparison: 0.97% [\u22126.10 to 5.32]).",
            "startOffset": 30338,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 32464,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "Post-booster, grade 3 solicited general symptoms were reported by 0.0\u20133.9% of investigational vaccine recipients and by 0.0\u20132.0% of PHiD-CV recipients (Fig. 3).",
            "startOffset": 32304,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 40202,
            "parents": [],
            "refoffsets": {
                "bib0135": {
                    "endOffset": 40201,
                    "startOffset": 40197
                }
            },
            "secId": "sec0070",
            "sentence": "Adults had circulating memory CD4+ T cells that could be stimulated by all tested antigens, whereas young children had a more limited response with non-memory type antigen-specific T cells [27].",
            "startOffset": 40008,
            "title": "Discussion"
        },
        {
            "endOffset": 24273,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0015",
            "sentence": "This study has been registered at www.clinicaltrials.gov (NCT00985751).",
            "startOffset": 24202,
            "title": "Study design and objectives"
        },
        {
            "endOffset": 27719,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "bib0115": {
                    "endOffset": 27718,
                    "startOffset": 27714
                }
            },
            "secId": "sec0030",
            "sentence": "Opsonophagocytic activity (OPA) for the above-mentioned antibodies was measured by a pneumococcal killing assay with a cut-off opsonic titer of 8, described previously [23].",
            "startOffset": 27546,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 32782,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "All large swelling reactions were local reactions around the injection site with a diameter of 53\u2013100 mm and onset on day 0 or 1 after vaccination.",
            "startOffset": 32635,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 26449,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0025",
            "sentence": "Serious adverse events (SAEs), defined as any medical occurrence that resulted in death, disability or incapacity, was life-threatening, or required hospitalization, were recorded over the whole study period.",
            "startOffset": 26241,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 24078,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0015",
            "sentence": "The study was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki.",
            "startOffset": 23980,
            "title": "Study design and objectives"
        },
        {
            "endOffset": 43396,
            "parents": [],
            "secId": "sec0075",
            "sentence": "R.P. declares he received payment for lectures, board membership, consultancy and attending meetings from GlaxoSmithKline group of companies and other vaccine manufacturers, and his institution received grants from GlaxoSmithKline group of companies.",
            "startOffset": 43146,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 31452,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "Incidences of solicited local grade 3 symptoms post-dose 1 and 2 were low (\u22649.6% of investigational vaccine recipients and \u22647.8% of PHiD-CV recipients) (Fig. 2).",
            "startOffset": 31291,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 28659,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0035",
            "sentence": "By pooling the groups, the target sample size of 60 toddlers per group (120 per pooled group) allowed for detection of a 10% increase in absolute values of the prevalence of grade 3 fever with at least 90% power.",
            "startOffset": 28447,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 31806,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "Irritability was the most common solicited general symptom following primary and booster vaccination (Fig. 3).",
            "startOffset": 31696,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 34174,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0060",
            "sentence": "In the PHiD-CV group, 85.0\u201385.4% of toddlers were seropositive for anti-PhtD antibodies at these post-vaccination timepoints (Table 1).",
            "startOffset": 34039,
            "title": "Immune response to pneumococcal proteins PhtD and Ply"
        },
        {
            "endOffset": 38270,
            "parents": [],
            "secId": "sec0070",
            "sentence": "No statistically significant difference was detected in the incidence of grade 3 fever following at least one primary vaccine dose between the investigational vaccines and PHiD-CV, confirming the primary objective.",
            "startOffset": 38056,
            "title": "Discussion"
        },
        {
            "endOffset": 40505,
            "parents": [],
            "refoffsets": {
                "bib0095": {
                    "endOffset": 40504,
                    "startOffset": 40500
                }
            },
            "secId": "sec0070",
            "sentence": "Further support to this hypothesis comes from the trial in adults preceding the current study, in which immune responses to Ply and PhtD after 2-dose priming with PHiD-CV/dPly/PhtD (10 or 30 \u03bcg formulation), measured by the same assay, seemed to be generally higher than reported here in toddlers [19].",
            "startOffset": 40203,
            "title": "Discussion"
        },
        {
            "endOffset": 27911,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0035",
            "sentence": "Safety and reactogenicity analyses were performed on the total vaccinated cohort (TVC), comprising all toddlers with at least one vaccine dose administration documented.",
            "startOffset": 27742,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 33367,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "Grade 3 unsolicited AEs were reported for 11 toddlers after primary vaccination (Table S1) and for one toddler after dPly/PhtD-30 booster vaccination (cystitis).",
            "startOffset": 33206,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 38354,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Reactogenicity of the investigational vaccines did not appear to be dose-dependent.",
            "startOffset": 38271,
            "title": "Discussion"
        },
        {
            "endOffset": 25822,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0020",
            "sentence": "No other vaccines were co-administered.",
            "startOffset": 25783,
            "title": "Participants and vaccines"
        },
        {
            "endOffset": 41096,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Measuring elicited antibody levels is the most common way of monitoring vaccine immunogenicity.",
            "startOffset": 41001,
            "title": "Discussion"
        },
        {
            "endOffset": 27333,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0030",
            "sentence": "Serotype-specific anti-capsular antibodies against the 10 PS-conjugates and two cross-reactive serotypes (6A, 19A) were measured using a GlaxoSmithKline 22F-inhibition enzyme-linked immunosorbent assay (ELISA), with a cut-off of 0.05 \u03bcg/mL.",
            "startOffset": 27093,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 43059,
            "parents": [],
            "secId": "sec0070",
            "sentence": "These results support further development of the investigational vaccines, including their evaluation in infants.",
            "startOffset": 42946,
            "title": "Discussion"
        },
        {
            "endOffset": 29867,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0045",
            "sentence": "Of the 257 vaccinated toddlers, 256 completed the study and 220 were included in the ATP cohort for immunogenicity (Fig. 1).",
            "startOffset": 29743,
            "title": "Study participants and demographics"
        },
        {
            "endOffset": 28843,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0035",
            "sentence": "The primary objective was reached if the asymptotic standardized 95% confidence interval (CI) of the defined difference included 0, or if the upper limit of this 95% CI was below 10%.",
            "startOffset": 28660,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 25722,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "bib0100": {
                    "endOffset": 25721,
                    "startOffset": 25717
                }
            },
            "secId": "sec0020",
            "sentence": "The fifth group received the licensed PHiD-CV [20].",
            "startOffset": 25671,
            "title": "Participants and vaccines"
        },
        {
            "endOffset": 41001,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Nevertheless, we observed increases in antibody GMCs, indicating priming and boosting effect in the toddler population.",
            "startOffset": 40882,
            "title": "Discussion"
        },
        {
            "endOffset": 41262,
            "parents": [],
            "refoffsets": {
                "bib0155": {
                    "endOffset": 41168,
                    "startOffset": 41164
                }
            },
            "secId": "sec0070",
            "sentence": "However, these levels do not always correlate well with protection [31] and a correlate of protection for pneumococcal protein vaccines has not yet been established.",
            "startOffset": 41097,
            "title": "Discussion"
        },
        {
            "endOffset": 38946,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Addition of dPly and PhtD to the conjugate vaccine formulations did not appear to have a negative effect on the immune response to the PS-conjugates.",
            "startOffset": 38797,
            "title": "Discussion"
        },
        {
            "endOffset": 24624,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0020",
            "sentence": "Eligible participants were healthy toddlers (12\u201323 months at first vaccination), without history of any hypersensitivity reaction following previous vaccination, and who had not previously been vaccinated against S. pneumoniae.",
            "startOffset": 24397,
            "title": "Participants and vaccines"
        },
        {
            "endOffset": 35771,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "In the groups that did not receive PS-conjugates, 0.0\u201317.1% of toddlers had antibody concentrations \u22650.2 \u03bcg/mL; similar ranges were observed pre- and post-vaccination (Table S2).",
            "startOffset": 35593,
            "title": "Immune response to pneumococcal serotype-specific PS-conjugates and to protein D"
        },
        {
            "endOffset": 41608,
            "parents": [],
            "secId": "sec0070",
            "sentence": "For antibodies against PhtD, no functional assays have yet been described.",
            "startOffset": 41534,
            "title": "Discussion"
        },
        {
            "endOffset": 22894,
            "parents": [],
            "secId": "sec0005",
            "sentence": "We evaluated the safety, reactogenicity and immunogenicity of investigational vaccine formulations containing dPly and PhtD, either alone or in combination with the PS-conjugates of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV; Synflorix\u2122, GlaxoSmithKline Vaccines), when administered to healthy toddlers.",
            "startOffset": 22534,
            "title": "Introduction"
        },
        {
            "endOffset": 23495,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0015",
            "sentence": "This phase II, randomized, observer-blind, controlled study (NCT00985751) was conducted in 10 centers in the Czech Republic between November 2009 and March 2011.",
            "startOffset": 23334,
            "title": "Study design and objectives"
        },
        {
            "endOffset": 44077,
            "parents": [],
            "secId": "sec0080",
            "sentence": "M.T. did the statistical analyses.",
            "startOffset": 44043,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 30023,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0045",
            "sentence": "One toddler in the PHiD-CV group was withdrawn due to a non-serious AE (eczema), not considered to be causally related to vaccination by the investigators.",
            "startOffset": 29868,
            "title": "Study participants and demographics"
        },
        {
            "endOffset": 37218,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "In all groups receiving formulations containing PS-conjugates, for each vaccine serotype, increases in antibody GMCs and OPA GMTs were observed from pre- to post-primary vaccination and from pre- to post-booster.",
            "startOffset": 37006,
            "title": "Immune response to pneumococcal serotype-specific PS-conjugates and to protein D"
        },
        {
            "endOffset": 37521,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "Post-dose 2, 97.4\u2013100% of toddlers in these groups were seropositive.",
            "startOffset": 37452,
            "title": "Immune response to pneumococcal serotype-specific PS-conjugates and to protein D"
        },
        {
            "endOffset": 44634,
            "parents": [],
            "secId": "sec0090",
            "sentence": "The results of this study were presented in part at the 8th International Symposium on Pneumococci & pneumococcal Diseases, Iguacu Falls, Brazil, March 11\u201315, 2012",
            "startOffset": 44471,
            "title": "Previous publications"
        },
        {
            "endOffset": 23806,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0015",
            "sentence": "Secondary objectives included safety, reactogenicity and immunogenicity assessment of the investigational vaccines.",
            "startOffset": 23691,
            "title": "Study design and objectives"
        },
        {
            "endOffset": 25265,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0020",
            "sentence": "All vaccines were administered intramuscularly with a 22\u201325 gauge needle (25 mm long) into the deltoid of the non-dominant arm or in the thigh if the deltoid size was inadequate.",
            "startOffset": 25087,
            "title": "Participants and vaccines"
        },
        {
            "endOffset": 31192,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "Incidences of solicited local and general symptoms after vaccination with the investigational formulations were generally within the same ranges as for PHiD-CV, except swelling which was reported less frequently post-dose 1 in the dPly/PhtD-30 group (Figs. 2 and 3).",
            "startOffset": 30926,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 28880,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0035",
            "sentence": "All other analyses were descriptive.",
            "startOffset": 28844,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 39017,
            "parents": [],
            "secId": "sec0070",
            "sentence": "No clear trend for dose-dependency of the immune response was observed.",
            "startOffset": 38946,
            "title": "Discussion"
        },
        {
            "endOffset": 35255,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "Before vaccination, for each vaccine serotype, a maximum of 15.8% of toddlers in the groups receiving formulations with PS-conjugates had serotype-specific antibody concentrations \u22650.2 \u03bcg/mL.",
            "startOffset": 35064,
            "title": "Immune response to pneumococcal serotype-specific PS-conjugates and to protein D"
        },
        {
            "endOffset": 36681,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "Post-primary vaccination, at least 80.0% of toddlers in the PHiD-CV/dPly/PhtD groups had OPA titers \u22658 for each vaccine serotype except for 6B (\u226574.1%), compared to 87.1% of toddlers in the PHiD-CV group.",
            "startOffset": 36477,
            "title": "Immune response to pneumococcal serotype-specific PS-conjugates and to protein D"
        },
        {
            "endOffset": 34038,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0060",
            "sentence": "In the investigational vaccine groups, these percentages increased to at least 97.7% one month post-dose 2 and pre-booster, reaching 100% post-booster.",
            "startOffset": 33887,
            "title": "Immune response to pneumococcal proteins PhtD and Ply"
        },
        {
            "endOffset": 38055,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Four investigational vaccine formulations containing dPly and PhtD, with or without PS-conjugates, showed a similar safety and reactogenicity profile to that of PHiD-CV in toddlers.",
            "startOffset": 37874,
            "title": "Discussion"
        },
        {
            "endOffset": 32303,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "Incidences of grade 3 solicited general symptoms ranged from 0.0% to 3.9% post-dose 1 and from 0.0% to 2.0% post-dose 2 in the investigational groups; none were reported for PHiD-CV, except irritability post-dose 2 (2.0%).",
            "startOffset": 32081,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 32634,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "Five large swelling reactions were reported: one occurring post-dose 1 and three post-booster in the PHiD-CV/dPly/PhtD-10 group, and one post-dose 2 in the PHiD-CV group.",
            "startOffset": 32464,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 37863,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "Anti-PD antibody GMCs increased from pre- to post-primary vaccination and from pre- to post-booster for all PD-containing formulations (Table 3A).",
            "startOffset": 37717,
            "title": "Immune response to pneumococcal serotype-specific PS-conjugates and to protein D"
        },
        {
            "endOffset": 30668,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "No grade 3 fever was reported post-dose 2 or post-booster.",
            "startOffset": 30610,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 44306,
            "parents": [],
            "secId": "sec0085",
            "sentence": "GlaxoSmithKline Biologicals SA was the funding source and was involved in all stages of the study conduct and analysis.",
            "startOffset": 44187,
            "title": "Funding"
        },
        {
            "endOffset": 38475,
            "parents": [],
            "secId": "sec0070",
            "sentence": "All dPly/PhtD-containing vaccines induced robust anti-protein immune responses following primary and booster vaccination.",
            "startOffset": 38354,
            "title": "Discussion"
        },
        {
            "endOffset": 30926,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "No statistically significant differences were detected in the incidence of grade 3 fever during primary vaccination with investigational formulations (protein alone or combined with PS-conjugates) compared to PHiD-CV; thus the primary objective was reached.",
            "startOffset": 30669,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 40881,
            "parents": [],
            "refoffsets": {
                "bib0140": {
                    "endOffset": 40880,
                    "startOffset": 40873
                },
                "bib0145": {
                    "endOffset": 40880,
                    "startOffset": 40873
                },
                "bib0150": {
                    "endOffset": 40880,
                    "startOffset": 40873
                }
            },
            "secId": "sec0070",
            "sentence": "This was not unexpected as naturally-acquired antibody levels against several pneumococcal protein surface antigens (including PhtD) and Ply have been reported to increase with age (from 6\u20139 months to 2 years) and exposure (nasopharyngeal carriage, acute otitis media) [28\u201330].",
            "startOffset": 40604,
            "title": "Discussion"
        },
        {
            "endOffset": 28446,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "refoffsets": {
                "bib0095": {
                    "endOffset": 28445,
                    "startOffset": 28441
                }
            },
            "secId": "sec0035",
            "sentence": "The groups were pooled based on the previously obtained safety results in adults, in which the number of participants reporting fever was similar for the respective 10 and 30 \u03bcg formulations [19].",
            "startOffset": 28250,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 24958,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0020",
            "sentence": "Participants were randomized (1:1:1:1:1) using a central internet randomization system (SBIR) to receive a 2-dose primary vaccination series followed by booster vaccination.",
            "startOffset": 24785,
            "title": "Participants and vaccines"
        },
        {
            "endOffset": 21578,
            "parents": [],
            "refoffsets": {
                "bib0015": {
                    "endOffset": 21577,
                    "startOffset": 21572
                },
                "bib0020": {
                    "endOffset": 21577,
                    "startOffset": 21572
                },
                "bib0025": {
                    "endOffset": 21577,
                    "startOffset": 21572
                }
            },
            "secId": "sec0005",
            "sentence": "Widespread use of these PCVs has significantly decreased the incidence of pneumococcal disease [3\u20135].",
            "startOffset": 21477,
            "title": "Introduction"
        },
        {
            "endOffset": 39539,
            "parents": [],
            "refoffsets": {
                "bib0125": {
                    "endOffset": 39431,
                    "startOffset": 39427
                },
                "bib0130": {
                    "endOffset": 39538,
                    "startOffset": 39534
                }
            },
            "secId": "sec0070",
            "sentence": "Dose-related increases in immunogenicity were also observed for other vaccine formulations containing 10 or 20 \u03bcg PhtD and pneumococcal choline-binding protein A (PcpA), with no further increase for the 50 \u03bcg dose [25], and for 10 and 25 \u03bcg doses of a dPly-containing vaccine, with no further increase for the 50 \u03bcg dose [26].",
            "startOffset": 39213,
            "title": "Discussion"
        },
        {
            "endOffset": 33206,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                }
            ],
            "secId": "sec0050",
            "sentence": "Unsolicited AEs considered vaccine-related were reported for one toddler (injection site fibrosis) following dPly/PhtD-10 primary vaccination, for two toddlers (vomiting and injection site fibrosis) after dPly/PhtD-10 booster, for one toddler (rhinitis) after PHiD-CV/dPly/PhtD-10 booster and for one toddler (rhinitis, insomnia and cough) after PHiD-CV/dPly/PhtD-30 booster.",
            "startOffset": 32831,
            "title": "Safety and reactogenicity"
        },
        {
            "endOffset": 39212,
            "parents": [],
            "refoffsets": {
                "bib0120": {
                    "endOffset": 39211,
                    "startOffset": 39207
                }
            },
            "secId": "sec0070",
            "sentence": "Another study evaluating different PhtD-containing formulations showed a stronger immune response to the 25 \u03bcg dose than to the 6 \u03bcg dose, but no difference between the 25 and 100 \u03bcg doses [24].",
            "startOffset": 39018,
            "title": "Discussion"
        },
        {
            "endOffset": 21476,
            "parents": [],
            "secId": "sec0005",
            "sentence": "Currently available pneumococcal conjugate vaccines (PCVs) contain capsular polysaccharides of the most prevalent pneumococcal serotypes, conjugated to a carrier protein (PS-conjugates).",
            "startOffset": 21290,
            "title": "Introduction"
        },
        {
            "endOffset": 34307,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0060",
            "sentence": "A high baseline seropositivity rate for anti-Ply antibodies (antibody concentrations \u2265599 LU/mL) was seen in all groups (75.0\u201388.6%).",
            "startOffset": 34174,
            "title": "Immune response to pneumococcal proteins PhtD and Ply"
        },
        {
            "endOffset": 41989,
            "parents": [],
            "secId": "sec0070",
            "sentence": "Moreover, further assessment of the biological impact of pneumococcal protein-containing vaccines in clinical studies evaluating impact on pneumococcal carriage or efficacy against disease endpoints will be valuable to assess their clinical value.",
            "startOffset": 41742,
            "title": "Discussion"
        },
        {
            "endOffset": 37645,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "At the pre-booster timepoint, 87.5\u201391.3% of PHiD-CV/dPly/PhtD recipients and 97.5% of PHiD-CV recipients were seropositive.",
            "startOffset": 37522,
            "title": "Immune response to pneumococcal serotype-specific PS-conjugates and to protein D"
        },
        {
            "endOffset": 22021,
            "parents": [],
            "secId": "sec0005",
            "sentence": "A substantial disease burden thus remained, necessitating the development of new vaccines that could provide broader protection.",
            "startOffset": 21893,
            "title": "Introduction"
        },
        {
            "endOffset": 26241,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0025",
            "sentence": "Symptom intensity was graded on a scale of 1 (mild) to 3 (severe).",
            "startOffset": 26175,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 26174,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0025",
            "sentence": "Solicited local and general symptoms were recorded within seven days post-vaccination and unsolicited AEs within 31 days post-vaccination.",
            "startOffset": 26036,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 44042,
            "parents": [],
            "secId": "sec0080",
            "sentence": "R.P., M.T., J.U.R. and D.B. planned and designed the study and interpreted the results.",
            "startOffset": 43955,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 39792,
            "parents": [],
            "secId": "sec0070",
            "sentence": "However, these studies involved adults whereas our study investigated toddlers, which could partially explain the difference in dose-dependency; toddlers have a less mature immune system which could result in a different immune response to vaccination.",
            "startOffset": 39540,
            "title": "Discussion"
        },
        {
            "endOffset": 24785,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0020",
            "sentence": "Toddlers were excluded if another vaccine had been administered, or planned, from 30 days before and up to 30 days after administration of a study vaccine dose.",
            "startOffset": 24625,
            "title": "Participants and vaccines"
        },
        {
            "endOffset": 25377,
            "parents": [
                {
                    "id": "sec0010",
                    "title": "Methodology"
                }
            ],
            "secId": "sec0020",
            "sentence": "Two groups received a formulation containing 10 or 30 \u03bcg of each dPly and PhtD (dPly/PhtD-10 and dPly/PhtD-30).",
            "startOffset": 25266,
            "title": "Participants and vaccines"
        },
        {
            "endOffset": 34461,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0060",
            "sentence": "Seropositivity rates increased in all investigational groups to at least 97.7% one month post-dose 2, and to 100% both pre- and post-booster vaccination.",
            "startOffset": 34308,
            "title": "Immune response to pneumococcal proteins PhtD and Ply"
        },
        {
            "endOffset": 37352,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "Booster vaccination elicited similar or higher antibody GMC and OPA GMT values compared to the post-dose 2 values (Tables 3A and 3B).",
            "startOffset": 37219,
            "title": "Immune response to pneumococcal serotype-specific PS-conjugates and to protein D"
        },
        {
            "endOffset": 42089,
            "parents": [],
            "refoffsets": {
                "bib0160": {
                    "endOffset": 42088,
                    "startOffset": 42084
                }
            },
            "secId": "sec0070",
            "sentence": "However, it is not yet clear which endpoints are adequate for licensure of these new vaccines [32].",
            "startOffset": 41990,
            "title": "Discussion"
        },
        {
            "endOffset": 21289,
            "parents": [],
            "refoffsets": {
                "bib0005": {
                    "endOffset": 21288,
                    "startOffset": 21283
                },
                "bib0010": {
                    "endOffset": 21288,
                    "startOffset": 21283
                }
            },
            "secId": "sec0005",
            "sentence": "Streptococcus pneumoniae, a leading cause of bacterial pneumonia and invasive disease, is responsible for approximately 11% of mortality in children under 5 years old worldwide [1,2].",
            "startOffset": 21106,
            "title": "Introduction"
        },
        {
            "endOffset": 22204,
            "parents": [],
            "refoffsets": {
                "bib0050": {
                    "endOffset": 22203,
                    "startOffset": 22196
                },
                "bib0055": {
                    "endOffset": 22203,
                    "startOffset": 22196
                },
                "bib0060": {
                    "endOffset": 22203,
                    "startOffset": 22196
                }
            },
            "secId": "sec0005",
            "sentence": "After the recent introduction of the 19A-containing 13-valent PCV, a decline in prevalence of serotype 19A was observed although it remained one of the most common serotypes [10\u201312].",
            "startOffset": 22022,
            "title": "Introduction"
        },
        {
            "endOffset": 36477,
            "parents": [
                {
                    "id": "sec0040",
                    "title": "Results"
                },
                {
                    "id": "sec0055",
                    "title": "Immunogenicity"
                }
            ],
            "secId": "sec0065",
            "sentence": "The percentage of toddlers with pneumococcal serotype-specific anti-capsular antibodies above 0.2 \u03bcg/mL were thus within similar ranges for the PHiD-CV/dPly/PhtD groups and the PHiD-CV group, both after 2-dose priming and post-booster (Table S2).",
            "startOffset": 36231,
            "title": "Immune response to pneumococcal serotype-specific PS-conjugates and to protein D"
        }
    ],
    "docId": "S0264410X14004356",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "prymula@fnhk.cz",
                "first": "Roman",
                "initial": "R.",
                "last": "Prymula"
            },
            {
                "email": "pazdiora@fnplzen.cz",
                "first": "Petr",
                "initial": "P.",
                "last": "Pazdiora"
            },
            {
                "email": "Magali.x.traskine@gsk.com",
                "first": "Magali",
                "initial": "M.",
                "last": "Traskine"
            },
            {
                "email": "jrueggeberg@doctors.org.uk",
                "first": "Jens U.",
                "initial": "J.U.",
                "last": "R\u00fcggeberg"
            },
            {
                "email": "dorota.d.borys@gsk.com",
                "first": "Dorota",
                "initial": "D.",
                "last": "Borys"
            }
        ],
        "doi": "10.1016/j.vaccine.2014.03.066",
        "firstpage": "3025",
        "issn": "0264410X",
        "keywords": [
            "DPly",
            "Immunogenicity",
            "PhtD",
            "Pneumococcal proteins",
            "Safety",
            "Toddler vaccination"
        ],
        "lastpage": "3034",
        "openaccess": "Full",
        "pub_year": 2014,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: A phase II randomized clinical trial"
    }
}